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OBJECTIVES: Establish the impact that present chemo-
therapy management is having on the quality of life (qol)
of patients being treated at the Prince Charles Hospital;
Allow comparison of the effect on the patients qol be-
tween established treatment modalities; Allow compari-
son of the effects on patients qol between established and
future trial treatment protocols. We report the interim
findings of this ongoing quality of life study. METH-
ODS: All patients referred for chemotherapy manage-
ment of their non-small cell lung cancer (NSCLC) were
asked to participate. The EORTC QLQ 30 and LC 13
were used to assess patients qol when disease restaging
tests were conducted. Data was entered into an access da-
tabase that allowed comparison. Protocols used were
CIV, CV- adjuvant-neoadjuvant setting. CG and single
agent Gemcitabine 1000mg/m2 on days 1, 8, 15, in the
palliative setting. RESULTS: Patients ages ranged 39 to
73 yrs, average age 53 yr, median, 51, mode 47years. The
sample consisted of 3 females & 12 males, 6 patients are
not reported, 3 neoadjuvant had progressive disease after
two cycles and were not followed, 3 palliative patients
died after one cycle of treatment. Of the 21 patients
treated 15 (71%) had improved Quality of Life scores
paralleled other measures of assessment. Scans show re-
sponse to single agent Gemzar in the palliative setting
and response to CIV in the neoadjuvant setting. CON-
CLUSION: we demonstrated 71% of our patients had
qol improvements. Management of patients with NSCLC
should consider chemotherapy. FUTURE DIRECTION:
An outcomes study is being conducted at two campuses
in Brisbane. This study seeks to include all newly diag-
nosed lung cancer patients and follow their progress
through their disease using clinical Quality of Life and
economic criteria to determine outcome. Comparison be-
tween treatment and within treatment arms will be com-
pared.
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OBJECTIVE: To critically evaluate the quality of health-
related quality of life (HRQoL) instruments for use in
clinical trials of non-small cell lung cancer (NSCLC).
METHODS: A structured review of literature was
conducted by searching MEDLINE (1975–2000) and
PsycINFO (1977–2000) using the keywords “lung can-
cer”, “quality of life” and “questionnaire”, and manu-
ally. HRQoL instruments that had been used in or de-
signed for lung cancer were selected for review. Each
instrument was assessed for its general features, feasibil-
ity, scoring and interpretation, and psychometric proper-
ties. RESULTS: Ten instruments were selected for review:
EORTC-QLQ30, EORTC-LC13, FACT-L, LCSS, FLIC,
CARES, CARES-SF, RSCL, FLIC and MQOL. Most
questionnaire items were appropriately generated through
multiple cycles of input from patients and clinicians. The
most studied psychometric properties were internal con-
sistency and convergent/divergent validity, with most in-
struments having Cronbach’s a 0.7 and acceptable cor-
relation coefficients for convergent/divergent validity.
Responsiveness, interpretability of the scale score, and
validity testing in cross-cultural settings were either inad-
equately evaluated or missing. All instruments have a
good readability level, an administration time less than
20 minutes, a time horizon of one week or less, and are
multilingual. All questionnaires have been used in clinical
trials for non-small cell lung cancer except CARES,
CARES-SF and MQOL. CONCLUSIONS: There are sev-
eral reliable and validated HRQoL instruments that are
appropriate for use in clinical trials of NCSLC. In partic-
ular, the EORTC-QLQ30 and its lung cancer supple-
ment, the LC13, LCSS, RSCL, FACT-L, and CARES
have greater evidence of good psychometric properties.
Further research is required to evaluate the cross-cultural
performance, score interpretability and correlation with
clinical outcomes of these instruments.
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BACKGROUND: Cancer of the head and neck is the
11th most common cancer in the US, however, there are
no published, comprehensive studies examining the costs
associated with the treatment of head and neck cancer in
the United States. The objective of this research was to
design a model to estimate the cost of treatment for squa-
mous cell carcinoma of the head and neck (SCCHN).
METHODS: A decision analytic model was designed to
project the outcomes and costs associated with SCCHN.
The model was stratified by site of disease, stage of pre-
sentation, treatment, and outcome. The most common
therapeutic options for SCCHN were modeled: 1) sur-
gery, 2) radiation therapy, 3) surgery and radiation ther-
apy, 4) radiation therapy and chemotherapy, and 5) palli-
ation. Base case data were obtained from the National
Cancer Data Base, the published literature, a modified
Delphi survey of experts, and an analysis of the Medicare
Standard Analytic Files. RESULTS: Average per patient
cost of care for SCCHN in the US was estimated to be
$20,876. Higher costs resulted for patients that present
with advanced cancers. The estimated cost of treating a
patient with Stage IV lip SCC ($19,274) was four times
that of Stage 0 lip SCC ($5,062). The site with the lowest
cost of treatment was lip ($7,261) while the highest cost
was associated with hypopharyngeal SCC ($28,584). The
cost per patient for palliative care ranged from $2,052
for lip SCC (28% of total cost of care) to $7,172 for si-
